Ocuphire Pharma Inc

R3X1-FF:Frankfurt Stock Exchange
RT Quote | Exchange | EUR
Last | 01/15/21 CET
5.75quote price arrow up+0.15 (+2.68%)
Volume
1,000
52 week range
5.20 - 6.15

...

Loading . . .

KEY STATS

  • Open5.65
  • Day High5.80
  • Day Low5.50
  • Prev Close5.80
  • 52 Week High6.15
  • 52 Week High Date01/05/21
  • 52 Week Low5.20
  • 52 Week Low Date01/04/21
  • Market Cap8.07M
  • Shares Out1.12M
  • 10 Day Average Volume653.4
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-27.76

RATIOS/PROFITABILITY

  • EPS (TTM)-5.35
  • P/E (TTM)-1.07
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Ocuphire Pharma Inc News

There is no recent news for this security.

Latest R3X1-FF News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of eye disorders. Its pipeline includes two small-molecule product candidates targeting front and back of the eye indications. The Company’s lead product candidate, Nyxol Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic...
Cam Gallagher
Chairman
Mina Sooch
President
Amy Rabourn
Chief Accounting Officer
Address
37000 Grand River Ave., Suite 120
Farmington Hills, MI
48335
United States